Drugs / 5-aminosalicylate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00167882 | Jul 2005 → Aug 2006 | Crohn disease, ulcerative colitis | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5-aminosalicylate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00167882 ↗ |
| Known as | 5ASA | “5ASA (Pentasa ® granules; Ferring) will be administered orally in dosages of 2 or 4 grams daily for a period of 4 weeks.” NCT00167882 ↗ |
| Known as | Pentasa | “5-aminosalicylate (Pentasa, Ferring)” NCT00167882 ↗ |
| Route | Oral | “5ASA (Pentasa ® granules; Ferring) will be administered orally in dosages of 2 or 4 grams daily for a period of 4 weeks.” NCT00167882 ↗ |